Clinical trial readout dates for Travere Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
| Phase 2 Sparsentan Focal Segmental Glomerulosclerosis; Minimal Change Disease · NCT05003986 | March 2027 Recruiting |
| Phase 1/2 Pegtibatinase Homocystinuria · NCT03406611 | July 2027 Recruiting |
| Phase 3 Pegtibatinase Homocystinuria · NCT06247085 | August 2027 Recruiting |
| Phase 3 Pegtibatinase Homocystinuria · NCT06431893 | August 2030 Enrolling |
Travere Therapeutics Inc. reported $472M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $52M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |